Voltar
Revisão Revisado por pares
BIBTEX RIS

T‐Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR‐ABL a

1993; Wiley; Volume: 690; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1993.tb44000.x

ISSN

1749-6632

Autores

Martin A. Cheever, Wei Chen, Mary L. Disis, Masazumi Takahashi, David Peace,

Tópico(s)

Cytomegalovirus and herpesvirus research

Resumo

Annals of the New York Academy of SciencesVolume 690, Issue 1 p. 101-112 T-Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR-ABLa MARTIN A. CHEEVER, MARTIN A. CHEEVER Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorWEI CHEN, WEI CHEN Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorMARY L. DISIS, MARY L. DISIS Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorMASAZUMI TAKAHASHI, MASAZUMI TAKAHASHI Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorDAVID J. PEACE, DAVID J. PEACE Department of Medicine Loyola University Chicago Maywood, Illinois 60153Search for more papers by this author MARTIN A. CHEEVER, MARTIN A. CHEEVER Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorWEI CHEN, WEI CHEN Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorMARY L. DISIS, MARY L. DISIS Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorMASAZUMI TAKAHASHI, MASAZUMI TAKAHASHI Division of Medical Oncology Mail Stop RM-17 University of Washington Seattle, Washington 98195Search for more papers by this authorDAVID J. PEACE, DAVID J. PEACE Department of Medicine Loyola University Chicago Maywood, Illinois 60153Search for more papers by this author First published: August 1993 https://doi.org/10.1111/j.1749-6632.1993.tb44000.xCitations: 27 a This work was supported by NIH Grants R37 CA30558, ROI CA54561, ROI CA57851, and T32 CA09515. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Cheever, M. A., D. B. Thompson, J. P. Klarnet & P. D. Greenberg. 1986. Antigen driven long-term cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy and persist long-term as functional memory T cells. J. Exp. Med. 163: 1100–1112. 10.1084/jem.163.5.1100 CASPubMedWeb of Science®Google Scholar 2 Chen, W., V. A. Reese & M. A. Cheever. 1990. Adoptively transferred antigen specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J. Immunol. 114: 3659–3666. Google Scholar 3 Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C.-R. Li, M. E. Agha & P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238–241. 10.1126/science.1352912 CASPubMedWeb of Science®Google Scholar 4 Baldwin, R. W. 1955. Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Brit. J. Cancer 9: 652–657. 10.1038/bjc.1955.70 CASPubMedWeb of Science®Google Scholar 5 Prehn, R. T. & J. M. Main. 1957. Immunity to methycholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18: 769–778. PubMedWeb of Science®Google Scholar 6 Klein, G., H. O. Sjögren, E. Klein & K. E. Hellström. 1960. Demonstration of resistance against methycholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20: 1561–1572. CASPubMedWeb of Science®Google Scholar 7 Vose, B. M. & G. D. Bonnard. 1982. Human tumor antigens defined by cytotoxic and proliferating responses of cultured lymphoid cells. Nature 296: 359–361. 10.1038/296359a0 CASPubMedWeb of Science®Google Scholar 8 Mitsuya, H., L. Matis, M. Megson, P. Bunn, C. Murray, D. Mann, R. Gallo & S. Broder. 1983. Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J. Exp. Med. 158: 994–999. 10.1084/jem.158.3.994 CASPubMedWeb of Science®Google Scholar 9 Anichini, A., A. Mazzocchi, G. Fossati & G. Parmiani. 1989. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells: Analysis of specificity and mechanisms of interaction. J. Immunol. 142: 3692–3701. PubMedWeb of Science®Google Scholar 10 Cozzolino, F., M. Torcia, A. M. Carossino, R. Giordani, C. Selli, C. Talini, E. Reali, A. Novelli, V. Pistoia & M. Ferrarini. 1987. Characterization of cells from invaded lymph nodes in patients with solid tumors: Lymphokine requirement for tumor-specific lymphoproliferative response. J. Exp. Med. 166: 303–318. 10.1084/jem.166.2.303 CASPubMedWeb of Science®Google Scholar 11 Slovin, S. F., R. D. Lackman, S. Ferrone, P. E. Kiely & M. I. Mastrangelo. 1986. Cellular immune response to human sarcomas: Cytotoxic T cell clones reactive with autologous sarcomas. J. Immunol. 137: 3042–3048. CASPubMedWeb of Science®Google Scholar 12 VAN DER Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van DEN Eynde, A. Knuth & T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647. 10.1126/science.1840703 PubMedWeb of Science®Google Scholar 13 Jerome, K. R., D. L. Barnd, K. M. Bendt, C. M. Boyer, J. Taylor-Papadimitriou, I. F. Mckenzie, R. C. Bast, Jr. & O. J. Finn. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51: 2908–2916. CASPubMedWeb of Science®Google Scholar 14 Barbacid, M. 1987. Ras genes. Ann. Rev. Biochem. 56: 779–827. 10.1146/annurev.bi.56.070187.004023 CASPubMedWeb of Science®Google Scholar 15 Bos, J. L. 1989. Ras oncogenes in human cancer. A review. Cancer Res. 49: 4682–4689. CASPubMedWeb of Science®Google Scholar 16 Bourne, H. R., D. A. Sanders & F. Mccormick. 1990. The GTPase superfamily: A conserved switch for diverse cell functions. Nature 348: 125–132. 10.1038/348125a0 CASPubMedWeb of Science®Google Scholar 17 Almoguera, C., D. Shibata, K. Forrester, J. Martin, N. Arnheim & M. Perucho. 1988. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 33: 549–554. 10.1016/0092-8674(88)90571-5 Web of Science®Google Scholar 18 Bos, J. L., E. R. Fearon, S. R. Hamilton, M. Verlaan-de Vries, J. H. Van Boom, A. J. Van Der Eb & B. Vogelstein. 1987. Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297. 10.1038/327293a0 CASPubMedWeb of Science®Google Scholar 19 Neri, A., J. P. Murphy, L. Cro, D. Ferrero, C. Tarella, L. Baldini & R. Dalla-Favera. 1989. Ras oncogene mutations in multiple myeloma. J. Exp. Med. 70: 1715–1725. 10.1084/jem.170.5.1715 Web of Science®Google Scholar 20 Stavnezer, E., I. Fogh & M. H. Wigler. 1983. Three human transforming genes are related to the viral ras oncogenes. Proc. Natl. Acad. Sci. USA 80: 2112–2116. 10.1073/pnas.80.8.2112 PubMedWeb of Science®Google Scholar 21 Reddy, F. P., R. K. Reynolds, E. Santos & M. Barbacid. 1982. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149–152. 10.1038/300149a0 CASPubMedWeb of Science®Google Scholar 22 Forrester, K., C. Almoguera, K. Han, W. E. Grizzle & M. Perucho. 1987. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298–303. 10.1038/327298a0 CASPubMedWeb of Science®Google Scholar 23 Cheever, M. A., W. Chen, H. Nelson, P. D. Greenberg, V. K. Lee, K. D. Crossland & D. J. Peace. 1990. T cell immunity to the oncogenic form of ras protein can be induced by immunization with synthetic peptides. In Cellular Immunity and Immunotherapy of Cancer. 295–302. M. T. Lotze & O. J. Finn, Eds. Wiley-Liss, Inc. New York . Google Scholar 24 Peace, D. J., W. Chen, H. Nelson & M. A. Cheever. 1991. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol. 146: 2059–2065. CASPubMedWeb of Science®Google Scholar 25 Peace, D. J., J. W. Smith, M. L. Disis, W. Chen & M. A. Cheever. T cells specific for the mutated segment of activated p21ras protein can be elicited by immunization in vivo with p21ras protein. J. Immunother., in press. Google Scholar 26 Niman, H. L., A. M. H. Thompson, A. Yu, M. Markman, J. J. Willems, H. A. Herwig, N. A. Habib, C. B. Wood, R. A. Houghten & R. A. Lerner. 1985. Anti-peptide antibodies detect oncogene-related proteins in urine. Proc. Natl. Acad. Sci. USA 82: 7924–7928. 10.1073/pnas.82.23.7924 CASPubMedWeb of Science®Google Scholar 27 Ng, S. C., P. Hamer, D. Petit, R. Delellis, H. Wolfe, D. Garlick & W. Carney. 1989. Detection and quantitation of ras p21 expression in normal and tumor tissues by ELISA. FASEB J. 3: 1511 (Abstr. 1657). Google Scholar 28 Miura, K., Y. Inoue, H. Nakamori, S. Iwai, E. Ohtsuka, M. Ikehara, S. Noguchi & S. Nishimura. 1986. Synthesis and expression of a synthetic gene for the activated human c-Ha-ras protein. Jpn Cancer Res. 77: 45–51. PubMedWeb of Science®Google Scholar 29 Pullano, T. G., E. Sinn & W. P. Carney. 1989. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma for v-Harvey-ras transgenic mouse. Oncogene 4: 1003–1008. CASPubMedWeb of Science®Google Scholar 30 Gaudernack, G., T. Gedde-Dahl, 3D, B. Fossum, B. H. Olsen, J. A. Eriksen & E. Thorsby. 1993. Oncogene derived peptides. A new class of tumor rejection antigens. J. Cell Biochem. Suppl. 17D: 109 (Abstr. NZ 208). Web of Science®Google Scholar 31 Falk, K., O. Rötzschke, S. Stevanovic, G. Jung & H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290–296. 10.1038/351290a0 CASPubMedWeb of Science®Google Scholar 32 Ljunggren, H.-G., N. J. Stam, C. ÖHlen, J. J. Neefjes, P. Höglund, M.-T. Heemels, J. Bastin, T. N. M. Schumacher, A. Townsend, K. Kärre & H. L. Ploegh. 1990. Empty MHC class I molecules come out in the cold. Nature 346: 476–480. 10.1038/346476a0 CASPubMedWeb of Science®Google Scholar 33 Peace, D. J., J. W. Smith, W. Chen, S.-G. You, W. L. Cosand, J. Blake & M. A. Cheever. Lysis of ras oncogene-transformed cells by cytotoxic T lymphocytes specific for the oncogenic p21ras protein. Submitted. Google Scholar 34 Konopka, J. B. & O. N. Witte. 1984. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37: 1035. 10.1016/0092-8674(84)90438-0 CASPubMedWeb of Science®Google Scholar 35 Shtivelman, E., B. Lifshitz, R. P. Gale & E. Canaani. 1985. Fused transcripts of abl and bcr genes in chronic myelogenous leukemia. Nature 315: 550. 10.1038/315550a0 CASPubMedWeb of Science®Google Scholar 36 Young, J. C. & O. N. Witte. 1988. Selective transformation of primitive lymphoid cells by the bcrlabl oncogene expressed in long-term lymphoid or myeloid culture. Molec. Cell Biol. 8: 4079–4087. 10.1128/MCB.8.10.4079 CASPubMedWeb of Science®Google Scholar 37 Szczylik, C., T. Skorski, N. C. Nicolaides, L. Manzella, L. Malaguarnera, D. Venturelli, A. M. Gewirtz, & B. Calabretta. 1991. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253: 562–565. 10.1126/science.1857987 CASPubMedWeb of Science®Google Scholar 38 Sullivan, K. M., P. Weiden, R. Storb, R. P. Witherspoon, A. Fefer, L. Fisher, C. D. Buckner, C. Anasetti, F. R. Appelbaum, C. Badger, P. Beatty, W. Bensinger, R. Berenson, C. Bigelow, M. A. Cheever, R. Clift, H. J. Deeg, K. Doney, P. Greenberg, J. A. Hansen, R. Hill, T. Loughran, P. Martin, P. Neiman, F. Peterson, J. Sanders, J. Singer, P. Stewart & E. D. Thomas. 1989. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73: 1720–1728. 10.1182/blood.V73.6.1720.1720 CASPubMedWeb of Science®Google Scholar 39 Chen, W., D. J. Peace, D. K. Rovira, S.-G. You & M. A. Cheever. 1992. T cell immunity to the joining region of p210bcr-abl protein. Proc. Natl. Acad. Sci. USA 89: 1468–1472. 10.1073/pnas.89.4.1468 CASPubMedWeb of Science®Google Scholar 40 Chen, W., S. G. You, M. L. Disis & M. A. Cheever. 1993. Evaluation of the joining region segment of p210BCR-ABL chimeric protein as a potential leukemia-specific antigen to elicit class I MHC-restricted CTL responses. J. Cell Biochem. (Abstr. Suppl. 17D): 107 (Abstr. NZ 203). PubMedWeb of Science®Google Scholar Citing Literature Volume690, Issue1Specific Immunotherapy of Cancer with VaccinesAugust 1993Pages 101-112 ReferencesRelatedInformation

Referência(s)